Bayer Must Face Bulk Of Takeda's Hemophilia Drug IP Suit
The vast majority of Takeda unit Baxalta's patent infringement suit against Bayer over competing hemophilia treatments will head to trial after a Delaware federal judge on Tuesday refused to make more...To view the full article, register now.
Already a subscriber? Click here to view full article